Stewart Alwyn Noble

USPTO Granted Patents = 27 (Patent Applications = 6)

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 1

Average Co-Inventor Count = 4.5

ph-index = 8

Forward Citations = 150(Granted Patents)

Location History:

Upper Saddle River, NJ (US) (2001 - 2003)
Lake Forest, IL (US) (2004)
Wheeling, IL (US) (2000 - 2006)
San Diego, CA (US) (2007 - 2015)

Company Filing History:

Synaptic Pharmaceutical Corporation

Alcon Laboratories, Inc.

9. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2000-2025

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12291708 - Oral delivery of antisense conjugates targeting PCSK9 (2025-05-06),

2. 9078887 - Bicyclic heteroaryl inhibitors of PDE4 (2015-07-14),

3. 8569300 - Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease (2013-10-29),

4. 8258154 - Bicyclic heteroaryl inhibitors of PDE4 (2012-09-04),

5. 8138205 - Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 (2012-03-20),

6. 8080566 - Carbazole inhibitors of histamine receptors for the treatment of disease (2011-12-20),

7. 8080563 - Bicyclic heteroaryl inhibitors of PDE4 (2011-12-20),

8. 7915253 - Sulfonyl-substituted bicyclic compounds as modulators of PPAR (2011-03-29),

9. 7834004 - Sulfonyl-substituted bicyclic compounds as modulators of PPAR (2010-11-16),

10. 7825256 - Inducible nitric oxide synthase dimerization inhibitors (2010-11-02),

11. 7745646 - Bicyclic heteroaryl inhibitors of PDE4 (2010-06-29),

12. 7494999 - Sulfonyl-substituted bicyclic compounds as modulators of PPAR (2009-02-24),

13. 7470722 - Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease (2008-12-30),

14. 7381749 - Sulfonamides as inhibitors of histone deacetylase for the treatment of disease (2008-06-03),

15. 7273880 - Selective NPY (Y5) antagonists (2007-09-25),

Title: Unveiling the Innovative Journey of Stewart Alwyn Noble

Introduction:

Stewart Alwyn Noble, a brilliant inventor hailing from San Diego, CA, has made significant contributions in the field of pharmaceuticals and treatments for inflammatory diseases. With a remarkable tally of 26 patents to his name, Noble stands out as a trailblazer in the realm of medical innovations.

Latest Patents:

Among his latest patents, "Bicyclic heteroaryl inhibitors of PDE4" showcases Noble's expertise in developing compounds to target phosphodiesterase 4 for treating inflammatory diseases. Additionally, his invention of "Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors" highlights his focus on combating a range of conditions from inflammatory to ocular diseases.

Career Highlights:

Noble's professional journey includes stints at renowned companies like Kalypsys, Inc. and Synaptic Pharmaceutical Corporation. His impactful work at these organizations has laid the foundation for groundbreaking advancements in pharmacology and drug development.

Collaborations:

Collaborating with esteemed colleagues such as Mohammad R Marzabadi and Andrew Shiau, Noble has been able to foster a culture of innovation and excellence. Together, they have pushed the boundaries of scientific research and development, leading to the creation of novel solutions for complex medical challenges.

Conclusion:

In conclusion, Stewart Alwyn Noble's unwavering dedication to innovation and his remarkable portfolio of patents underscore his profound impact on the pharmaceutical industry. His pioneering work continues to inspire future generations of inventors and researchers in their quest to improve healthcare and enhance the quality of life for people worldwide.

This text is generated by artificial intelligence and may not be accurate.